Avenue Therapeutics Net Debt Growth & History (ATXI)
Avenue Therapeutics's net debt was −$2.9M for fiscal 2025.
View full Avenue Therapeutics company overviewAvenue Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$2.9M | −$261,000 | — |
| 2024 | 2024-12-31 | −$2.6M | −$811,000 | — |
| 2023 | 2023-12-31 | −$1.8M | $4.9M | — |
| 2022 | 2022-12-31 | −$6.7M | −$2.9M | — |
| 2021 | 2021-12-31 | −$3.8M | −$631,000 | — |
| 2020 | 2020-12-31 | −$3.1M | $5.6M | — |
| 2019 | 2019-12-31 | −$8.7M | −$6.1M | — |
| 2018 | 2018-12-31 | −$2.7M | $9.1M | — |
| 2017 | 2017-12-31 | −$11.8M | −$11.8M | — |
| 2016 | 2016-12-31 | $3,000 | — | — |
Avenue Therapeutics quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$1.9M | $1.4M | — |
| Q1 2026 | 2026-03-31 | −$2.4M | $1.1M | — |
| Q4 2025 | 2025-12-31 | −$2.9M | −$261,000 | — |
| Q3 2025 | 2025-09-30 | −$3.7M | −$1.1M | — |
| Q2 2025 | 2025-06-30 | −$3.3M | $1.6M | — |
| Q1 2025 | 2025-03-31 | −$3.5M | −$308,000 | — |
| Q4 2024 | 2024-12-31 | −$2.6M | −$811,000 | — |
| Q3 2024 | 2024-09-30 | −$2.6M | −$2.4M | — |
| Q2 2024 | 2024-06-30 | −$4.9M | −$3.3M | — |
| Q1 2024 | 2024-03-31 | −$3.2M | $5.0M | — |
| Q4 2023 | 2023-12-31 | −$1.8M | $4.9M | — |
| Q3 2023 | 2023-09-30 | −$161,000 | $56,000 | — |
| Q2 2023 | 2023-06-30 | −$1.6M | −$681,000 | — |
| Q1 2023 | 2023-03-31 | −$8.2M | −$6.4M | — |
| Q4 2022 | 2022-12-31 | −$6.7M | −$2.9M | — |
| Q3 2022 | 2022-09-30 | −$217,000 | $368,000 | — |
| Q2 2022 | 2022-06-30 | −$890,000 | $231,000 | — |
| Q1 2022 | 2022-03-31 | −$1.8M | −$8,000 | — |
| Q4 2021 | 2021-12-31 | −$3.8M | −$631,000 | — |
| Q3 2021 | 2021-09-30 | −$585,000 | $3.7M | — |
| Q2 2021 | 2021-06-30 | −$1.1M | $4.1M | — |
| Q1 2021 | 2021-03-31 | −$1.8M | $4.7M | — |
| Q4 2020 | 2020-12-31 | −$3.1M | $5.6M | — |
| Q3 2020 | 2020-09-30 | −$4.3M | $4.4M | — |
| Q2 2020 | 2020-06-30 | −$5.3M | $5.2M | — |
| Q1 2020 | 2020-03-31 | −$6.6M | $22.9M | — |
| Q4 2019 | 2019-12-31 | −$8.7M | −$6.1M | — |
| Q3 2019 | 2019-09-30 | −$8.7M | −$3.9M | — |
| Q2 2019 | 2019-06-30 | −$10.5M | −$1.5M | — |
| Q1 2019 | 2019-03-31 | −$29.4M | −$14.5M | — |
| Q4 2018 | 2018-12-31 | −$2.7M | $9.1M | — |
| Q3 2018 | 2018-09-30 | −$4.8M | $11.2M | — |
| Q2 2018 | 2018-06-30 | −$8.9M | $25.7M | — |
| Q1 2018 | 2018-03-31 | −$15.0M | −$15.2M | — |
| Q4 2017 | 2017-12-31 | −$11.8M | −$11.8M | — |
| Q3 2017 | 2017-09-30 | −$16.1M | — | — |
| Q2 2017 | 2017-06-30 | −$34.7M | — | — |
| Q1 2017 | 2017-03-31 | $204,000 | — | — |
| Q4 2016 | 2016-12-31 | $3,000 | — | — |
Avenue Therapeutics net debt trends
Over the last five fiscal years, Avenue Therapeutics's net debt increased from −$3.1M to −$2.9M, a change of $277,000. The latest reported quarter, Q2 2026, shows −$1.9M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Avenue Therapeutics source filings ↗